Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2

Switching to the 2-drug regimen dolutegravir + rilpivirine demonstrated noninferiority vs continuing a 3-drug or 4-drug current antiretroviral regimen (CAR) at week 48 and maintained high levels of virologic suppression to week 148 in the SWORD studies. We report inflammation and atherogenesis bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Llibre, Josep M., López Cortés, Luis Fernando, Aylott, Alicia, Wynne, Brian, Matthews, Jessica, Van Solingen-Ristea, Rodica, Vandermeulen, Kati, van Wyk, Jean, Kahl, Lesley P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377491/
https://www.ncbi.nlm.nih.gov/pubmed/35551149
http://dx.doi.org/10.1097/QAI.0000000000003019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377491/
https://www.ncbi.nlm.nih.gov/pubmed/35551149
http://dx.doi.org/10.1097/QAI.0000000000003019

Ejemplares similares